Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Filings indexed 361 across all filing types
Latest filing 2024-05-28 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Regulatory Filings
2024-05-28 English
Restricted Share Award Scheme
Regulatory Filings Classification · 1% confidence The document is a placeholder message from the Hong Kong Exchanges and Clearing Limited stating that the requested document has been removed by the issuer. Since it does not contain any substantive financial or corporate information and serves as a system-generated notice regarding a missing filing, it falls under the general regulatory announcement category.
2024-05-28 English
Post-IPO Share Option Scheme
Regulatory Filings Classification · 1% confidence The document is a placeholder message from the Hong Kong Exchanges and Clearing Limited stating that the requested document has been removed by the issuer. Since it does not contain any substantive financial or corporate information and serves as a system-generated notice regarding a missing filing, it falls under the general regulatory announcement category.
2024-05-28 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE I CLINICAL TRIAL OF JSKN016 FOR THE TREATMENT OF ADVANCED MALIGNANT SOLID TUMORS
Regulatory Filings
2024-05-21 English
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, JUNE 12, 2024
Regulatory Filings
2024-05-20 English
NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2024-05-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.